2. Signaling Pathways
  3. SOS1
  4. SOS1 Inhibitor

SOS1 Inhibitor

SOS1 Inhibitors (17):

Cat. No. Product Name Effect Purity
  • HY-151881
    SOS1-IN-15
    		Inhibitor 99.51%
    SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM. SOS1-IN-15 is a promising agent candidate for the research of KRAS-driven cancer.
  • HY-151517
    SOS1-IN-14
    		Inhibitor 99.60%
    SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817).
  • HY-144962
    SOS1-IN-11
    		Inhibitor 98.22%
    SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM.
  • HY-158310
    SOS1/EGFR-IN-1
    		Inhibitor 99.54%
    SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM).
  • HY-144212
    SOS1-IN-8
    		Inhibitor
    SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).
  • HY-153989
    SOS1-IN-16
    		Inhibitor
    SOS1-IN-16 (Comp 54) is a selective inhibitor of SOS1 with an IC50 of 7.2 nM. SOS1-IN-16 has inhibitory activity of CYP3A4 when using testosterone as a substrate, with an IC50 of 8.9μM. SOS1-IN-16 can be used for cancer research.
  • HY-144211
    SOS1-IN-7
    		Inhibitor
    SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
  • HY-145046
    SOS1-IN-3
    		Inhibitor
    SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
  • HY-144965
    SOS1-IN-12
    		Inhibitor
    SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
  • HY-144213
    SOS1-IN-10
    		Inhibitor
    SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
  • HY-145047
    SOS1-IN-4
    		Inhibitor
    SOS1-IN-4 is a potent SOS1 inhibitor with an IC50 of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65).
  • HY-132129
    SOS1-IN-2
    		Inhibitor
    SOS1-IN-2 (Compound 1-1) is an inhibitor of SOS1 with an IC50 value of 5 nM. SOS1-IN-2 can be used in tumor research.
  • HY-145048
    SOS1-IN-5
    		Inhibitor
    SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4).
  • HY-153940
    SOS1/KRAS-IN-1
    		Inhibitor
    SOS1/KRAS-IN-1(Compound 2) is a SOS1/KRAS inhibitor, which can be used in the research of SOS1/KRAS-mediated diseases.
  • HY-144207
    SOS1-IN-9
    		Inhibitor
    SOS1-IN-9 is a potent SOS1 inhibitor with an IC50 of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302).
  • HY-144210
    SOS1-IN-6
    		Inhibitor
    SOS1-IN-6 (compound 33-P1) is a potent SOS1 inhibitor with IC50s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively.
  • HY-144967
    SOS1-IN-13
    		Inhibitor
    SOS1-IN-13 is a potent son of sevenless homolog 1 (SOS1) inhibitor with IC50s of 6.5 nM and 327 nM for SOS1 and pERK, respectively. SOS1-IN-13 can be used for researching anticancer.